BioCryst Pharmaceuticals Inc (BCRX.OQ)

BCRX.OQ on NASDAQ Stock Exchange Global Select Market

9.83USD
3:55pm EDT
Price Change (% chg)

$-0.66 (-6.29%)
Prev Close
$10.49
Open
$10.48
Day's High
$10.48
Day's Low
$9.82
Volume
262,963
Avg. Vol
324,487
52-wk High
$14.62
52-wk Low
$4.56

BCRX.OQ

Chart for BCRX.OQ

About

BioCryst Pharmaceuticals, Inc. (BioCryst) is a biotechnology company. BioCryst designs, optimizes and develops drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on therapeutic areas. Peramivir is its product, which is a neuraminidase inhibitor for the treatment of patients with influenza. The... (more)

Overall

Beta: 2.12
Market Cap (Mil.): $752.72
Shares Outstanding (Mil.): 71.76
Dividend: --
Yield (%): --

Financials

  BCRX.OQ Industry Sector
P/E (TTM): -- 128.81 33.98
EPS (TTM): -0.63 -- --
ROI: -61.15 -1.84 17.39
ROE: -94.31 -6.63 18.24
Search Stocks

BioCryst expects to begin Ebola study in weeks

- BioCryst Pharmaceuticals Inc said it expects to initiate a study within weeks to test its antiviral in primates for use against Ebola infections

29 Aug 2014

UPDATE 1-BioCryst expects to begin Ebola study in weeks

Aug 29 - BioCryst Pharmaceuticals Inc said it expects to initiate a study within weeks to test its antiviral in primates for use against Ebola infections

29 Aug 2014

BioCryst expects to begin Ebola study in weeks

Aug 29 - BioCryst Pharmaceuticals Inc said it expects to initiate a study within weeks to test its antiviral in primates for use in Ebola, as it was awarded an additional $2.4 million in U.S. government funding.

29 Aug 2014

U.S. government advances development of BioCryst's potential Ebola drug

- BioCryst Pharmaceuticals Inc said the U.S. government exercised options to test the company's antiviral drug in humans and non-primates as a treatment for hemorrhagic fever viruses such as Ebola.

13 Aug 2014

U.S. govt advances development of BioCryst's potential Ebola drug

Aug 13 - BioCryst Pharmaceuticals Inc said the U.S. government exercised options to test the company's antiviral drug in humans and non-primates as a treatment for hemorrhagic fever viruses such as Ebola.

13 Aug 2014

As virus spreads, investors bet on potential Ebola cures

- Investors are showering attention on drug developers working on a potential treatment for the Ebola virus, even if some of the drugs are a long way from production.

08 Aug 2014

BioCryst hereditary disorder drug succeeds in trial, shares jump

- BioCryst Pharmaceuticals Inc's oral drug to prevent a hereditary disorder characterized by abnormal swelling was effective in reducing attacks, sending the drugmaker's shares up as much as 22 percent.

27 May 2014

UPDATE 2-BioCryst hereditary disorder drug succeeds in trial, shares jump

* Drug, if approved, will be first oral preventive for hereditary angioedema

27 May 2014

BioCryst's immune disorder drug succeeds in mid-stage trial

May 27 - BioCryst Pharmaceuticals Inc said its experimental drug for treating a rare immune disorder was effective in reducing the attacks of the disease in a mid-stage trial.

27 May 2014

Competitors

  Price Change
DAIICHI SANKYO COMPANY, LIMITED (4568.T) ¥1,721 -17.00
Eisai Co., Ltd (4523.T) ¥4,435 -23.50
Roche Holding Ltd. (ROG.VX) CHF283.10 +2.40
GlaxoSmithKline plc (GSK.L) 1,413.00p -7.50
Shire PLC (SHP.L) 5,340.00p -25.00
Shire PLC (3159084.L) -- --

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks